دورية أكاديمية
Strategies for Improving Impaired Osseointegration in Compromised Animal Models.
| العنوان: | Strategies for Improving Impaired Osseointegration in Compromised Animal Models. |
|---|---|
| المؤلفون: | Deng J; Department of Biomedical Engineering, College of Engineering, Virginia Commonwealth University, Richmond, VA, USA., Van Duyn C; Department of Biomedical Engineering, College of Engineering, Virginia Commonwealth University, Richmond, VA, USA., Cohen DJ; Department of Biomedical Engineering, College of Engineering, Virginia Commonwealth University, Richmond, VA, USA., Schwartz Z; Department of Biomedical Engineering, College of Engineering, Virginia Commonwealth University, Richmond, VA, USA.; Department of Periodontics, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA., Boyan BD; Department of Biomedical Engineering, College of Engineering, Virginia Commonwealth University, Richmond, VA, USA.; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, USA. |
| المصدر: | Journal of dental research [J Dent Res] 2024 May; Vol. 103 (5), pp. 467-476. Date of Electronic Publication: 2024 Apr 15. |
| نوع المنشور: | Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Sage Country of Publication: United States NLM ID: 0354343 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1544-0591 (Electronic) Linking ISSN: 00220345 NLM ISO Abbreviation: J Dent Res Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Thousand Oaks, CA : Sage Original Publication: Chicago, American Dental Assn. [etc.] |
| مواضيع طبية MeSH: | Osseointegration*/physiology , Dental Implants* , Surface Properties* , Disease Models, Animal* , Bone-Implant Interface*, Animals ; Osteoblasts/physiology ; Humans ; Osteogenesis/physiology ; Osteoclasts ; Dental Implantation, Endosseous |
| مستخلص: | Implant osseointegration is reduced in patients with systemic conditions that compromise bone quality, such as osteoporosis, disuse syndrome, and type 2 diabetes. Studies using rodent models designed to mimic these compromised conditions demonstrated reduced bone-to-implant contact (BIC) or a decline in bone mineral density. These adverse effects are a consequence of disrupted intercellular communication. A variety of approaches have been developed to compensate for the altered microenvironment inherent in compromised conditions, including the use of biologics and implant surface modification. Chemical and physical modification of surface properties at the microscale, mesoscale, and nanoscale levels to closely resemble the surface topography of osteoclast resorption pits found in bone has proven to be a highly effective strategy for improving implant osseointegration. The addition of hydrophilicity to the surface further enhances osteoblast response at the bone-implant interface. These surface modifications, applied either alone or in combination, improve osseointegration by increasing proliferation and osteoblastic differentiation of osteoprogenitor cells and enhancing angiogenesis while modulating osteoclast activity to achieve net new bone formation, although the specific effects vary with surface treatment. In addition to direct effects on surface-attached cells, the communication between bone marrow stromal cells and immunomodulatory cells is sensitive to these surface properties. This article reports on the advances in titanium surface modifications, alone and in combination with novel therapeutics in animal models of human disease affecting bone quality. It offers clinically translatable perspectives for clinicians to consider when using different surface modification strategies to improve long-term implant performance in compromised patients. This review supports the use of surface modifications, bioactive coatings, and localized therapeutics as pragmatic approaches to improve BIC and enhance osteogenic activity from both structural and molecular standpoints. Competing Interests: Declaration of Conflicting InterestsThe authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: BDB is a paid consultant for Medtronic Spine. The Laboratory for Musculoskeletal Research and Innovation at Virginia Commonwealth University (Boyan/Schwartz/Cohen) laboratory receives Ti disks and implants from Institut Straumann AG (Basel, Switzerland) and Ti6Al4V disks and implants from AB Dental (Ashdod, Israel), as well as Medtronic (Minneapolis, MN, USA). All authors declare no potential conflicts of interest with respect to the authorship and/or publication of this article. |
| References: | J Musculoskelet Neuronal Interact. 2019 Mar 1;19(1):79-93. (PMID: 30839306) Clin Oral Implants Res. 2020 Apr;31(4):374-387. (PMID: 31953969) Pharmaceutics. 2022 Feb 21;14(2):. (PMID: 35214186) Orthop Surg. 2022 Jun;14(6):1217-1228. (PMID: 35451209) Int J Periodontics Restorative Dent. 2000 Aug;20(4):366-73. (PMID: 11203576) Clin Implant Dent Relat Res. 2016 Apr;18(2):253-60. (PMID: 26864614) Implant Dent. 2019 Feb;28(1):11-19. (PMID: 30461438) J Clin Endocrinol Metab. 2014 Dec;99(12):E2504-9. (PMID: 25050899) Eur Radiol Exp. 2019 Apr 11;3(1):17. (PMID: 30972589) J Oral Rehabil. 2014 Jun;41(6):443-76. (PMID: 24612346) J Orthop Surg Res. 2021 Jan 14;16(1):59. (PMID: 33446235) J Prosthodont. 2009 Jun;18(4):309-23. (PMID: 19210307) Bioact Mater. 2021 Oct 19;12:169-184. (PMID: 35310387) J Clin Periodontol. 2006 Dec;33(12):929-35. (PMID: 17092244) Br J Oral Maxillofac Surg. 2015 Oct;53(8):748-53. (PMID: 26093969) Clin Oral Implants Res. 2019 Aug;30(8):777-790. (PMID: 31104360) Biomaterials. 2021 Jan;267:120464. (PMID: 33130322) Exp Biol Med (Maywood). 2019 Nov;244(16):1493-1503. (PMID: 31615285) Biomimetics (Basel). 2023 Feb 25;8(1):. (PMID: 36975323) Exp Physiol. 2022 Apr;107(4):265-282. (PMID: 35178802) Diabetes Metab Syndr Obes. 2020 Jun 30;13:2279-2288. (PMID: 32636662) Int J Oral Maxillofac Implants. 2000 Nov-Dec;15(6):811-8. (PMID: 11151579) J Clin Periodontol. 2007 Jul;34(7):610-7. (PMID: 17433044) Mol Med Rep. 2018 Jan;17(1):1591-1598. (PMID: 29138818) Trends Endocrinol Metab. 2022 May;33(5):333-344. (PMID: 35307247) Acta Biomater. 2023 Feb;157:236-251. (PMID: 36435442) Regen Biomater. 2022 Feb 24;9:rbac011. (PMID: 35480856) Acta Biomater. 2019 Oct 1;97:578-586. (PMID: 31349056) Clin Oral Investig. 2023 Jun;27(6):2483-2493. (PMID: 37043030) Dent Mater. 2021 Apr;37(4):690-700. (PMID: 33589272) Bone. 2021 Dec;153:116145. (PMID: 34390886) J Clin Periodontol. 2017 Jun;44(6):636-648. (PMID: 28346753) Natl J Maxillofac Surg. 2013 Jul;4(2):142-50. (PMID: 24665167) Indian J Med Res. 2007 Mar;125(3):451-72. (PMID: 17496368) Int J Implant Dent. 2016 Dec;2(1):9. (PMID: 27747701) ACS Biomater Sci Eng. 2023 Aug 14;9(8):4720-4734. (PMID: 37491189) Int J Mol Sci. 2020 Feb 12;21(4):. (PMID: 32059603) Tissue Eng Part B Rev. 2013 Jun;19(3):233-53. (PMID: 23088597) Int J Oral Maxillofac Implants. 2014 Nov-Dec;29(6):1293-300. (PMID: 25397793) Int J Oral Maxillofac Surg. 2015 Jun;44(6):798-805. (PMID: 25813087) Int J Nanomedicine. 2020 May 18;15:3523-3537. (PMID: 32547011) Br Dent J. 2014 Oct;217(8):425-30. (PMID: 25342349) Oral Dis. 2018 Mar;24(1-2):253-260. (PMID: 29480621) J Oral Rehabil. 2017 Mar;44(3):220-228. (PMID: 27981620) Biomed Pharmacother. 2020 Dec;132:110911. (PMID: 33125972) Sci Rep. 2016 Apr 25;6:24562. (PMID: 27109829) Molecules. 2021 Apr 29;26(9):. (PMID: 33947088) Bone. 2020 Apr;133:115266. (PMID: 32044333) J Dent. 2013 Mar;41(3):195-206. (PMID: 23313715) Endocrine. 2019 Apr;64(1):184-195. (PMID: 30826991) Bone. 2017 Oct;103:188-199. (PMID: 28711659) J Periodontal Res. 2017 Aug;52(4):761-771. (PMID: 28321876) Clin Oral Implants Res. 2011 Apr;22(4):406-15. (PMID: 21303420) J Orthop Res. 2021 Sep;39(9):1908-1920. (PMID: 33002223) Clin Implant Dent Relat Res. 2017 Aug;19(4):616-623. (PMID: 28480634) Int J Oral Maxillofac Implants. 2010 May-Jun;25(3):516-24. (PMID: 20556250) J Biomater Appl. 2021 Sep;36(3):552-561. (PMID: 34162236) Dent Mater J. 2023 Jan 31;42(1):11-18. (PMID: 36123044) Int J Oral Maxillofac Implants. 2016 Sep-Oct;31(5):1189-94. (PMID: 27632277) J Evid Based Dent Pract. 2016 Jun;16(2):124-6. (PMID: 27449843) Clin Implant Dent Relat Res. 2017 Jun;19(3):423-431. (PMID: 27990756) Periodontol 2000. 2015 Jun;68(1):99-121. (PMID: 25867982) Adv Drug Deliv Rev. 2023 Aug;199:114900. (PMID: 37263543) |
| معلومات مُعتمدة: | R01 AR072500 United States AR NIAMS NIH HHS |
| فهرسة مساهمة: | Keywords: bone diseases; bone regeneration; bone-implant interface; diabetes mellitus; metabolic; osteoporosis; surface properties; type 2 |
| المشرفين على المادة: | 0 (Dental Implants) |
| تواريخ الأحداث: | Date Created: 20240415 Date Completed: 20240426 Latest Revision: 20240509 |
| رمز التحديث: | 20240509 |
| مُعرف محوري في PubMed: | PMC11055505 |
| DOI: | 10.1177/00220345241231777 |
| PMID: | 38616679 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1544-0591 |
|---|---|
| DOI: | 10.1177/00220345241231777 |